Professor of Chemical Engineering Eva Martín del Valle foresees in vitro testing within two years of an aerosol against lung cancer, thanks to the aid granted by the Ramón Areces Foundation.

Now that the anti-cancer drugs have been proven effective, research is focusing on finding new treatments that minimize side effects and, above all, are more selective in eliminating cancer cells and preserving healthy cells. How to vehicle these therapies has thus become a fundamental line of assay for more direct and effective forms of targeting tumors.

In this context, the Professor of Chemical Engineering at the University of Salamanca, Eva Martín del Valle, a pioneer in Spain in applying this area of ​​knowledge to biomedicine, has achieved an unprecedented advance in the design of a non-toxic alternative to Chemotherapy through the use of intelligent nanocapsules capable of recognizing and applying the drug directly to tumor cells.

Thanks to the recent help received from the Ramón Areces Foundation, the USAL scientific team is trying to modify conventional chemotherapy – specifically lung cancer – by developing an aerosol that works as a conventional inhaler and includes a smart vehicle capable of recognizing only the tumor cells, thus minimizing the toxic effects. Furthermore it does not generate any type of adverse reaction in contact with lung tissue, according to the person responsible for the project.

The aerosol will also offer the patient autonomy in the administration of a conventional cycle of drugs. “What we are trying to do is to abolish the dependence of the patient who has to spend two hours undergoing treatment in a room while receiving chemotherapy”, in addition to reducing the “amount of drug used to get to specific targets”, says the person in charge of the project. This will reduce toxicity and increase efficacy, since virtually “80% of the drug supplied is not used, but has to be metabolized or expelled by the body”, Eva Martín del Valle explained.

With the new funding obtained, 120,000 euros for the next three years, the researcher estimates that in two years, “or maybe less”, they can begin to carry out in vivo tests in mice.

Posted by Juan M. Corchado

Juan Manuel Corchado (15 May 1971, Salamanca, Spain) is Professor at the University of Salamanca. He has been Vice-Rector for Research from 2013 to 2017 and Director of the Science Park of the University of Salamanca. Elected as Dean of the Faculty of Science twice, he holds a PhD in Computer Science from the University of Salamanca and a PhD in Artificial Intelligence from the University of the West of Scotland. He leads the renowned BISITE (Bioinformatics, Intelligent Systems and Educational Technology) Research Group, created in 2000. Director of the IoT Digital Innovation Hub and President of the AIR Institute, J. M. Corchado is also Visiting Professor at the Osaka Institute of Technology since January 2015, Visiting Professor at the Universiti Malaysia Kelantan and Member of the Advisory Group on Online Terrorist Propaganda of the European Counter Terrorism Centre (EUROPOL). J. M. Corchado has been president of the IEEE Systems, Man and Cybernetics Society, and academic coordinator of the University Institute for Research in Art and Animation Technology at the University of Salamanca, as well as researcher at the Universities of Paisley (UK), Vigo (Spain) and the Plymouth Marine Laboratory (UK). He currently combines all his activity with the direction of Master programmes in Security, Digital Animation, Mobile Telephony, Information Systems Management, Internet of Things, Social Media, 3D Design and Printing, Blockchain, Z System, Industry 4.0, Agile Project Management, and Smart Cities & Intelligent Buildings, at the University of Salamanca and his work as editor-in-chief of the journals ADCAIJ (Advances in Distributed Computing and Artificial Intelligence Journal), OJCST (Oriental Journal of Computer Science and Technology) or Electronics MDPI (Computer Science & Engineering section). J. M. Corchado mainly works on projects related to Artificial Intelligence, Machine Learning, Blockchain, IoT, Fog Computing, Edge Computing, Smart Cities, Smart Grids and Sentiment Analysis. He has recently been included in the board of trustees of the AstraZeneca Foundation, along with other health professionals and researchers recognised for bringing scientific knowledge closer to society.

Thanks for your comment

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.